Pharma Marketing News
News & Views for
Responsible Marketers

Messages from Our Sponsors

Pharma Glossary

Pharmaguy's Picks

Pharma Marketing Network Curated Content Forums
The Leading Online Source of Curated Content for Pharmaceutical Marketing Experts
Newsletter | Conferences | Podcasts | Glossary | Surveys | Blog | Advertising Information | Contact Us

"Must Read Blog for Insiders." -- Wall Street Journal
Pharma Marketing News
Current Issue of Pharma Marketing News Available!

Search the Entire Pharma Marketing Forums Site

Go Back   Pharma Marketing Network Curated Content > News & Views > Industry News

Industry News Pharmaceutical industry news from newsfeeds, press releases, news stories, etc.

Thread Tools Rate Thread Display Modes
Old 15th April 2011, 06:22 AM
Pharma Newshound Pharma Newshound is offline
News Gatherer
Join Date: Dec 2007
Location: USA
Posts: 11,037
Default Bye Bye Alli!

Source: WSJ

Glaxo to Shed Its OTC Diet Drug, Alli


Four years after launching the nonprescription diet pill Alli with much fanfare and a heavy marketing budget, U.K. drug maker GlaxoSmithKline PLC on Thursday said that it plans to sell off the drug along with a clutch of other over-the-counter brands.

Glaxo once tipped Alli as a possible blockbuster, but sales never took off, and the drug was hurt last year by reports that a small number of people taking it experienced liver damage.

Glaxo had already announced several months ago that it planned to sell over-the-counter brands with about 500 million ($813 million) in annual sales. On Thursday, it listed the brands to be sold, including Alli, the analgesics Solpadeine and Goody's and the vitamin brand Abtei.

When Glaxo launched Alli in 2007, it backed the drug with an extravagant marketing campaign that included television, print and Internet ads and elaborate in-store displays. It set up a website where Alli users could swap dieting tips and get advice from dieticians. Glaxo even published a book with diet advice and recipes, which it sold at drugstores.

But sales sputtered soon after the June 2007 U.S. launch. Glaxo sold 150 million of Alli that year, and only 75 million in 2008. Sales rallied in 2009 to 203 million as Glaxo launched Alli throughout Europe, but the company acknowledged in February that demand for the drug was falling in the U.S. and Europe. The company didn't break out Alli sales in 2010.

Alli is a weaker, nonprescription version of the prescription drug Xenical, which is marketed by Roche Holding AG. Last year, the U.S. Food and Drug Administration said both drugs should carry new warnings about rare reports of "severe liver injury," although the agency said it wasn't clear whether the drugs caused the injury.

The watchdog group Public Citizen has called for both drugs to be banned due to liver-injury reports, and repeated this call again Thursday.

Glaxo defended Alli's safety in a statement Thursday, saying it was "safe and effective when used as directed." The company said it was selling Alli and the other brands because it "lacked sufficient critical mass in some product categories and certain brands have lacked focus due to other global priorities."

Alli works by blocking the gut from absorbing some fat from food. Diet drugs are a tough sell, because of their limited efficacy and because most dieters quickly abandon their weight-loss plans. Glaxo hoped to fight that phenomenon by marketing Alli as only part of a sensible dieting plan that also needed to include healthy eating and exercise.
Pharma Newshound
"I sift through the news so you don't have to!"

Please take the PMN Forums Visitor Survey and help us provide a better experience. It will only take 1 minute of your time.

Got news? Tell me about it:
Reply With Quote

Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

All times are GMT -5. The time now is 04:12 AM.

Powered by vBulletin® Version 3.6.4
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
(c) 2014, Pharma Marketing Network. All rights reserved.